SavedAdd your journal

Journals / Medical Records / 2026 / Sayı: 1

Predictors of 10-Year Survival After Transcatheter Aortic Valve Replacement with First-Generation Aortic Valve: Insights from A Single Center Initial Experience

İlk Nesil Aort kapağı ile Transkateter Aort Kapak Replasmanı Sonrası 10 Yıllık Sağkalımın Belirleyicileri: Tek Merkezin Erken Deneyim Bulguları

Ayşe Hoşoğlu(BAŞKENT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-2875-1952
Merih Kutlu(KARADENİZ TEKNİK ÜNİVERSİTESİ)0000-0001-5331-8563
Ömer Gedikli(KARADENİZ TEKNİK ÜNİVERSİTESİ)0000-0003-3848-9692
Hüseyin İnce(Vivantes - Netzwerk für Gesundheit GmbH Klinikum Neukölln)0000-0002-5982-8983
Pages
—
Publication Date
2026-03-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings emphasize the critical role of precise patient evaluation and underscore the potential value of personalized procedural strategies to optimize long-term outcomes in TAVR patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: This study aimed to identify predictors of 10-year survival in patients undergoing early Transcatheter Aortic Valve Replacement (TAVR) with the first-generation CoreValve system, providing insights from a pioneering single-center experience in Turkey.
📊
Key Findings & Data:Material and Methods: We retrospectively analyzed high-risk patients who underwent TAVR between April 2012 and March 2013.
💡
Conclusion & Impact:These findings emphasize the critical role of precise patient evaluation and underscore the potential value of personalized procedural strategies to optimize long-term outcomes in TAVR patients
🔬Design:Modeling & Simulation
📍Scope:2012 Verileri
⚙️Variables:Transkateter Aort Kapak Replasmanı · Sağkalım Analizi · Uzun Dönem Sonuç

Abstract

Aim: This study aimed to identify predictors of 10-year survival in patients undergoing early Transcatheter Aortic Valve Replacement (TAVR) with the first-generation CoreValve system, providing insights from a pioneering single-center experience in Turkey. Material and Methods: We retrospectively analyzed high-risk patients who underwent TAVR between April 2012 and March 2013. Baseline clinical characteristics and echocardiographic parameters were compared between survivors and non-survivors over a 10-year follow-up period. Survival analysis was performed using Kaplan-Meier curves, and Cox regression models were utilized to identify independent predictors of survival. Results: The cohort included patients with a mean age of 77.1 ± 7.7 years. The Kaplan–Meier analysis estimated the median survival time at 62 months (95% CI: 33–127), with a mean survival time of 71.6 months (95% CI: 43.9–99.3). Survivors exhibited significantly lower left ventricular (LV) end-diastolic diameter, LV mass index, and LV diastolic-systolic diameter difference compared to non-survivors. In univariate analysis, STS score, pulmonary artery pressure (PAP), LV hypertrophy pattern, LV diameter difference, and LV mass index emerged as potential predictors of long-term survival. STS score and LV diameter difference were independent predictors. Conclusion: In this study, both STS score and LV diastolic-systolic diameter difference were identified as independent predictors of 10-year survival following TAVR. These findings emphasize the critical role of precise patient evaluation and underscore the potential value of personalized procedural strategies to optimize long-term outcomes in TAVR patients

Özet

Amaç: Bu çalışma, Türkiye’deki öncü bir merkezin erken dönem deneyiminden yola çıkarak, ilk nesil CoreValve sistemi ile Transkateter Aort Kapak Replasmanı (TAVR) uygulanan hastalarda 10 yıllık sağkalımın öngördürücülerini belirlemeyi amaçlamaktadır. Gereç ve Yöntem: Nisan 2012 ile Mart 2013 arasında TAVR uygulanan yüksek riskli hastalar retrospektif olarak analiz edildi. On yıllık takip süresi boyunca sağ kalan ve kaybedilen hastaların başlangıçtaki klinik özellikleri ve ekokardiyografik parametreleri karşılaştırıldı. Sağkalım analizi Kaplan-Meier eğrileri ile yapıldı, Cox regresyon modelleriyle bağımsız öngördürücüler belirlendi. Bulgular: Çalışmaya dâhil edilen hastaların ortalama yaşı 77 ± 7.9 yıl olup, ortanca sağkalım süresi 76.3 ± 57.6 aydı. Sağ kalan hastalarda, sol ventrikül (LV) diyastol sonu çapı, LV kitle indeksi ve LV diyastol-sistol çap farkı anlamlı şekilde daha düşüktü. STS skoru, pulmoner arter basıncı (PAB), LV hipertrofi paterni, LV çap farkı ve LV kitle indeksi uzun dönem sağkalımın bağımsız öngördürücüleri olarak saptandı. Sonuç: STS skoru, pulmoner arter basıncı ve sol ventrikül geometrik yeniden yapılanması, TAVR sonrası 10 yıllık sağkalımı anlamlı şekilde etkilemektedir. Bulgular, hasta değerlendirmesinde yüksek hassasiyetin önemini vurgulamakta ve uzun dönem sonuçların iyileştirilmesi için kişiye özel TAVR stratejilerinin değerine işaret etmektedir.

🔖

Cite This Article

Hoşoğlu, A., Kutlu, M., Gedikli, Ö., İnce, H. (2026). Predictors of 10-Year Survival After Transcatheter Aortic Valve Replacement with First-Generation Aortic Valve: Insights from A Single Center Initial Experience. Medical Records, Sayı: 1. https://doi.org/10.37990/medr.1714483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (46)

  1. Srinivasan A, Wong F, Wang B. Transcatheter aortic valve replacement: Past, present, and future. Clinical cardiology. Jan 2024;47(1):e24209. doi:10.1002/clc.24209
  2. Ternacle J, Hecht S, Eltchaninoff H, et al. Durability of transcatheter aortic valve implantation. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Jul 15 2024;20(14):e845-e864. doi:10.4244/eij-d-23-01050
  3. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal. Feb 12 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395
  4. Cesario V, Oliva O, De Biase C, et al. Who Lives Longer, the Valve or the Patient? The Dilemma of TAVI Durability and How to Optimize Patient Outcomes. Journal of clinical medicine. Oct 14 2024;13(20)doi:10.3390/jcm13206123
  5. Généreux P, Iung B. TAVI in asymptomatic patients with severe aortic stenosis: pros and cons. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Nov 18 2022;18(10):793-795. doi:10.4244/eij-e-22-00043
  6. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. The New England journal of medicine. Apr 28 2016;374(17):1609-20. doi:10.1056/NEJMoa1514616
  7. Talanas G, Laconi A, Kereiakes DJ, et al. Long-Term Outcomes of Transcatheter vs Surgical Aortic Valve Replacement: Meta-analysis of Randomized Trials. Journal of the Society for Cardiovascular Angiography & Interventions. Jul 2024;3(7):102143. doi:10.1016/j.jscai.2024.102143
  8. Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. European heart journal. Apr 1 2024;45(13):1116-1124. doi:10.1093/eurheartj/ehae043
  9. Salaun E, Mahjoub H, Girerd N, et al. Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve Replacement. Circulation. Sep 4 2018;138(10):971-985. doi:10.1161/circulationaha.118.035150
  10. Tastet L, Tribouilloy C, Maréchaux S, et al. Staging Cardiac Damage in Patients With Asymptomatic Aortic Valve Stenosis. Journal of the American College of Cardiology. Jul 30 2019;74(4):550-563. doi:10.1016/j.jacc.2019.04.065
  11. Généreux P, Pibarot P, Redfors B, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. European heart journal. Dec 1 2017;38(45):3351-3358. doi:10.1093/eurheartj/ehx381
  12. Okuno T, Heg D, Lanz J, et al. Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. International journal of cardiology Heart & vasculature. Apr 2021;33:100768. doi:10.1016/j.ijcha.2021.100768
  13. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. Jan 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003
  14. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Feb 2 2021;143(5):e35-e71. doi:10.1161/cir.0000000000000932
  15. Ajmal Z, Rehman ZU, Ishtiaq A, et al. Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Moderate-Risk Patients With Aortic Stenosis: A Systematic Review of Clinical Trials. Cureus. Sep 2024;16(9):e70268. doi:10.7759/cureus.70268
  16. Hoşoğlu A. Merkezimizde transkateter aort kapak implantasyonu yapılan hastalarda erken ve geç dönem sonuçlar. 2016;
  17. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. The New England journal of medicine. Oct 21 2010;363(17):1597-607. doi:10.1056/NEJMoa1008232
  18. Buellesfeld L, Gerckens U, Schuler G, et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. Journal of the American College of Cardiology. Apr 19 2011;57(16):1650-7. doi:10.1016/j.jacc.2010.11.044
  19. Yakubov SJ, Adams DH, Watson DR, et al. 2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. Journal of the American College of Cardiology. Sep 22 2015;66(12):1327-34. doi:10.1016/j.jacc.2015.07.042
  20. O'Hair D, Yakubov SJ, Grubb KJ, et al. Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk. JAMA cardiology. Feb 1 2023;8(2):111-119. doi:10.1001/jamacardio.2022.4627
  21. Yücel G, Paker T, Akçevin A, et al. [Transcatheter aortic valve implantation: the first applications and early results in Turkey]. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir. Jun 2010;38(4):258-63. Transkateter aort kapak yerleştirme: Türkiye'deki ilk uygulamalar ve erken sonuçlar.
  22. Magyari B, Kittka B, Goják I, et al. Learning Curve for Starting a Successful Single-Centre TAVR Programme with Multiple Devices: Early and Mid-Term Follow-Up. Journal of clinical medicine. Feb 14 2024;13(4)doi:10.3390/jcm13041088
  23. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. Journal of the American College of Cardiology. Nov 8 2011;58(20):2130-8. doi:10.1016/j.jacc.2011.08.050
  24. Şentürk B, Dursun H, Çöllüoğlu T, et al. Evaluation of structural valve deterioration and bioprosthetic valve failure utilizing the new European consensus definition in patients undergoing TAVI with first-generation devices: Outcomes beyond 5 years from a single center in Turkey. Anatolian journal of cardiology. Aug 2021;25(8):579-587. doi:10.5152/AnatolJCardiol.2021.37670
  25. Elbasha K, Kaur J, Abdelghani M, et al. Ten-year Durability, Hemodynamic Performance, and Clinical Outcomes after Transcatheter Aortic Valve Implantation Using a Self-expanding Device. Cardiology and therapy. Sep 2024;13(3):529-540. doi:10.1007/s40119-024-00369-2
  26. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet (London, England). Jun 20 2015;385(9986):2477-84. doi:10.1016/s0140-6736(15)60308-7
  27. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. European heart journal. Jan 2011;32(2):205-17. doi:10.1093/eurheartj/ehq406
  28. Testa L, Latib A, Brambilla N, et al. Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. European heart journal. May 21 2020;41(20):1876-1886. doi:10.1093/eurheartj/ehz925
  29. Sathananthan J, Lauck S, Polderman J, et al. Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. Feb 15 2021;97(3):E431-e437. doi:10.1002/ccd.29124
  30. Panico RA, Giannini C, De Carlo M, et al. Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Mar 20 2019;14(16):1639-1647. doi:10.4244/eij-d-18-00779
  31. Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation. Dec 4 2018;138(23):2597-2607. doi:10.1161/circulationaha.118.036866
  32. Testa L, Giannini C, Costa G, et al. Transcatheter aortic valve replacement with corevalve self-expanding bioprosthesis: Clinical and durability data up to 12 years. Cardiovascular revascularization medicine: including molecular interventions. Apr 2025;73:23-30. doi:10.1016/j.carrev.2024.07.013
  33. Biancari F, D'Errigo P, Barbanti M, et al. Ten-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients: The OBSERVANT study. International journal of cardiology Heart & vasculature. Dec 2024;55:101545. doi:10.1016/j.ijcha.2024.101545
  34. Khalil S, Tabowei G, Kaur M, et al. Effect of Pulmonary Hypertension on Survival Outcomes in Patients With Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Cureus. Apr 2024;16(4):e58540. doi:10.7759/cureus.58540
  35. Chau KH, Douglas PS, Pibarot P, et al. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. Journal of the American College of Cardiology. May 19 2020;75(19):2446-2458. doi:10.1016/j.jacc.2020.03.042
  36. Verdecchia P, Angeli F, Mazzotta G, et al. Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. Journal of the American Heart Association. May 24 2017;6(6)doi:10.1161/jaha.117.005948
  37. Tadic M, Cuspidi C, Vukomanovic V, Kocijancic V, Celic V. The impact of different left ventricular geometric patterns on right ventricular deformation and function in hypertensive patients. Archives of cardiovascular diseases. May 2016;109(5):311-20. doi:10.1016/j.acvd.2015.12.006
  38. Tadic M, Cuspidi C, Vukomanovic V, Kocijancic V, Celic V. Right ventricular remodeling and updated left ventricular geometry classification: is there any relationship? Blood pressure. Oct 2016;25(5):292-7. doi:10.3109/08037051.2016.1172868
  39. Dweck MR, Loganath K, Bing R, et al. Multi-modality imaging in aortic stenosis: an EACVI clinical consensus document. European heart journal Cardiovascular Imaging. Oct 27 2023;24(11):1430-1443. doi:10.1093/ehjci/jead153
  40. Ternacle J, Hecht S, Eltchaninoff H, et al. Durability of transcatheter aortic valve implantation. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Jul 15 2024;20(14):e845-e864. doi:10.4244/eij-d-23-01050
  41. Généreux P, Iung B. TAVI in asymptomatic patients with severe aortic stenosis: pros and cons. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Nov 18 2022;18(10):793-795. doi:10.4244/eij-e-22-00043
  42. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. Jan 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003
  43. Yücel G, Paker T, Akçevin A, et al. [Transcatheter aortic valve implantation: the first applications and early results in Turkey]. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir. Jun 2010;38(4):258-63. Transkateter aort kapak yerleştirme: Türkiye'deki ilk uygulamalar ve erken sonuçlar.
  44. Sathananthan J, Lauck S, Polderman J, et al. Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. Feb 15 2021;97(3):E431-e437. doi:10.1002/ccd.29124
  45. Panico RA, Giannini C, De Carlo M, et al. Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Mar 20 2019;14(16):1639-1647. doi:10.4244/eij-d-18-00779
  46. Testa L, Giannini C, Costa G, et al. Transcatheter aortic valve replacement with corevalve self-expanding bioprosthesis: Clinical and durability data up to 12 years. Cardiovascular revascularization medicine: including molecular interventions. Apr 2025;73:23-30. doi:10.1016/j.carrev.2024.07.013